Developer docs
API playgroundTry for free, no card

Search company profiles

F-Prime

Full company profile

uuid00005ug

Namestring
F-Prime
Legal namestring
Impresa Management LLC
Company typeenum
Private
Founded yearint
1970
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, early-stage investing, healthcare investments, technology investments, crypto investing
Industry1 code
PRIMARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital Investment
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeManaged Services
Description

Generates returns through exits, IPOs, and distributions from portfolio company investments. Manages $5.3 billion in assets under management with no outside investors.

fprimecapital.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Fintech Index
Description

F-Prime's fintech index platform that monitors the performance of emerging, publicly traded financial technology companies.

fprimecapital.com
Core offering1 text field

F-Prime Capital is a private venture capital firm that invests equity capital in early-stage companies across life sciences, technology, healthtech + services, and crypto sectors. The firm provides strategic guidance, operational support, and access to its network to help portfolio companies scale, and also publishes the F-Prime Fintech Index tracking publicly traded fintechs. Advisory services are delivered through Impresa Management LLC, and F-Prime also advises Fine Structure Ventures.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

F-Prime Capital is a venture capital and investment advisory firm that manages $5.3 billion in assets under management. The firm makes early-stage investments in category-defining companies across life sciences, technology, healthtech + services, and crypto sectors. F-Prime operates as a multi-sector VC with a portfolio of 400+ global portfolio companies, including over 35 companies that were started from scratch. The firm has generated 52 IPOs and maintains offices in Cambridge, MA, London, UK, and San Francisco, CA. F-Prime does not offer a distinct technology product; rather, it provides investment capital, strategic partnership, and operational support to founders in the healthcare and technology sectors.

Product and service4 records
1F-Prime Capital Investment Services
CategoryVenture Capital Investment
Description

Venture capital investment and advisory services providing equity funding, strategic guidance, and operational support to early-stage companies in life sciences, technology, healthtech + services, and crypto sectors. The firm manages $5.3 billion in assets under management and has produced 52 IPOs across 400+ portfolio companies.

2F-Prime Fintech Index
CategoryMarket Intelligence / Index Tracking
Description

F-Prime's fintech index platform that monitors the performance of emerging, publicly traded financial technology companies.

3Fine Structure Ventures Advisory
CategoryInvestment Advisory Services
Description

Advisory services provided to Fine Structure Ventures (finestructure.vc) as of July 1, 2024, with F-Prime providing investment advisory support to the fund.

4Science2Startup Conference
CategoryIndustry Events
Description

Annual conference hosted by F-Prime for life sciences founders and investors, supporting top-of-funnel deal sourcing and ecosystem engagement.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Multi-stage venture firm investing across technology, healthcare/biotech, and crypto with a stage-agnostic approach and similar breadth of sectors. Closest direct competitor given overlapping thesis areas (enterprise software, fintech, crypto, healthtech) and comparable AUM scale.

TypeDirect peer
Description

Multi-stage VC with stage-agnostic healthcare and technology investing, including creation/incubation of companies. Comparable given shared focus on healthtech services, fintech, and biotech, plus similar Harvard/Cambridge ecosystem roots.

TypeDirect peer
Description

Long-tenured life sciences and technology venture firm with deep biotech focus and ability to write large, long-duration checks. Comparable given overlapping portfolio companies (Beam, Denali, Aviadobio) and stage-agnostic life sciences approach.

TypeBroad incumbent
Description

Multi-stage venture firm with similar longevity (>50 years) investing across healthcare, technology, and emerging sectors globally. Comparable in breadth and global footprint, though Sequoia operates at substantially larger AUM scale.

TypeDirect peer
Description

Long-tenured multi-stage venture firm with healthcare and technology focus across stages. Comparable given similar longevity, multi-decade track record, and stage-agnostic healthcare investing approach.

TypeDirect peer
Description

Multi-stage venture firm with enterprise, consumer, fintech, and healthcare investments. Comparable given overlapping portfolio activity (Pie Series A, Jump Series B, Meld funding) and stage-agnostic posture.

TypeDirect peer
Description

Large, multi-stage venture firm with healthcare and technology focus. Comparable given similar long-duration, multi-sector approach and ability to back companies from formation through growth.

TypeEmerging player
Description

Corporate venture arm of Alphabet with multi-stage healthcare and technology investing. Comparable given shared portfolio companies (Rippl, Paradigm Health) and similar stage-agnostic approach, though narrower sector focus.

TypeDirect peer
Description

Multi-stage venture firm with bold, long-duration bets across technology, healthcare, and frontier sectors. Comparable given stage-agnostic posture and willingness to incubate companies from inception.

TypeDirect peer
Description

Healthcare-dedicated investment firm with stage-agnostic approach across therapeutics, medtech, and digital health. Comparable given shared focus on biotech creation and similar portfolio overlap (Apreo Health, R1 Therapeutics-adjacent areas).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment563 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

F-Prime

Venture Capital Investmentfprimecapital.com

F-Prime firmographics

Firmographics
Name
F-Prime
Legal name
Impresa Management LLC
Website
https://fprimecapital.com
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

F-Prime industry classification

Industry
Product category
Venture Capital Investment
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Venture capital
  • Early-stage investing
  • Healthcare investments
  • Technology investments
  • Crypto investing

Where F-Prime is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices3 records

Markets served

F-Prime business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Venture Capital Returns: Generates returns through exits, IPOs, and distributions from portfolio company investments. Manages $5.3 billion in assets under management with no outside investors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

F-Prime product offering

Product offering

Core offering

F-Prime Capital is a private venture capital firm that invests equity capital in early-stage companies across life sciences, technology, healthtech + services, and crypto sectors. The firm provides strategic guidance, operational support, and access to its network to help portfolio companies scale, and also publishes the F-Prime Fintech Index tracking publicly traded fintechs. Advisory services are delivered through Impresa Management LLC, and F-Prime also advises Fine Structure Ventures.

Product overview

F-Prime Capital is a venture capital and investment advisory firm that manages $5.3 billion in assets under management. The firm makes early-stage investments in category-defining companies across life sciences, technology, healthtech + services, and crypto sectors. F-Prime operates as a multi-sector VC with a portfolio of 400+ global portfolio companies, including over 35 companies that were started from scratch. The firm has generated 52 IPOs and maintains offices in Cambridge, MA, London, UK, and San Francisco, CA. F-Prime does not offer a distinct technology product; rather, it provides investment capital, strategic partnership, and operational support to founders in the healthcare and technology sectors.

Differentiator

Problem solved

Functional benefit

Brands

  • Fintech Index: F-Prime's fintech index platform that monitors the performance of emerging, publicly traded financial technology companies.

Products and services

  • F-Prime Capital Investment Services Venture capital investment and advisory services providing equity funding, strategic guidance, and operational support to early-stage companies in life sciences, technology, healthtech + services, and crypto sectors. The firm manages $5.3 billion in assets under management and has produced 52 IPOs across 400+ portfolio companies.
  • F-Prime Fintech Index F-Prime's fintech index platform that monitors the performance of emerging, publicly traded financial technology companies.
  • Fine Structure Ventures Advisory Advisory services provided to Fine Structure Ventures (finestructure.vc) as of July 1, 2024, with F-Prime providing investment advisory support to the fund.
  • Science2Startup Conference Annual conference hosted by F-Prime for life sciences founders and investors, supporting top-of-funnel deal sourcing and ecosystem engagement.

Companies that use F-Prime

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

F-Prime technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

F-Prime partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

F-Prime competitors and assessment

Company assessment

Direct peers

  • Andreessen Horowitz: Multi-stage venture firm investing across technology, healthcare/biotech, and crypto with a stage-agnostic approach and similar breadth of sectors. Closest direct competitor given overlapping thesis areas (enterprise software, fintech, crypto, healthtech) and comparable AUM scale.
  • General Catalyst: Multi-stage VC with stage-agnostic healthcare and technology investing, including creation/incubation of companies. Comparable given shared focus on healthtech services, fintech, and biotech, plus similar Harvard/Cambridge ecosystem roots.
  • ARCH Venture Partners: Long-tenured life sciences and technology venture firm with deep biotech focus and ability to write large, long-duration checks. Comparable given overlapping portfolio companies (Beam, Denali, Aviadobio) and stage-agnostic life sciences approach.
  • Bessemer Venture Partners: Long-tenured multi-stage venture firm with healthcare and technology focus across stages. Comparable given similar longevity, multi-decade track record, and stage-agnostic healthcare investing approach.
  • Lightspeed Venture Partners: Multi-stage venture firm with enterprise, consumer, fintech, and healthcare investments. Comparable given overlapping portfolio activity (Pie Series A, Jump Series B, Meld funding) and stage-agnostic posture.
  • New Enterprise Associates (NEA): Large, multi-stage venture firm with healthcare and technology focus. Comparable given similar long-duration, multi-sector approach and ability to back companies from formation through growth.
  • Khosla Ventures: Multi-stage venture firm with bold, long-duration bets across technology, healthcare, and frontier sectors. Comparable given stage-agnostic posture and willingness to incubate companies from inception.
  • OrbiMed: Healthcare-dedicated investment firm with stage-agnostic approach across therapeutics, medtech, and digital health. Comparable given shared focus on biotech creation and similar portfolio overlap (Apreo Health, R1 Therapeutics-adjacent areas).

Broad incumbents

  • Sequoia Capital: Multi-stage venture firm with similar longevity (>50 years) investing across healthcare, technology, and emerging sectors globally. Comparable in breadth and global footprint, though Sequoia operates at substantially larger AUM scale.

Emerging players

  • GV (Google Ventures): Corporate venture arm of Alphabet with multi-stage healthcare and technology investing. Comparable given shared portfolio companies (Rippl, Paradigm Health) and similar stage-agnostic approach, though narrower sector focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

F-Prime social profiles

Digital presence

F-Prime financial estimates

Financial estimate

Revenue estimate

Valuation estimate

F-Prime leadership team

Management profile

Number of profiles

Profiles17 records

F-Prime subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

F-Prime funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

F-Prime M&A and investment

M&A and investment

M&A

Investments563 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about F-Prime

What does F-Prime do?

F-Prime Capital is a private venture capital firm that invests equity capital in early-stage companies across life sciences, technology, healthtech + services, and crypto sectors. The firm provides strategic guidance, operational support, and access to its network to help portfolio companies scale, and also publishes the F-Prime Fintech Index tracking publicly traded fintechs. Advisory services are delivered through Impresa Management LLC, and F-Prime also advises Fine Structure Ventures.

Is F-Prime a public or private company?

F-Prime is a private company. It is classified as corporate owned and is currently operating.

When was F-Prime founded?

F-Prime was founded in 1970. It employs 101 to 250 people.

Where is F-Prime based?

F-Prime is headquartered in Cambridge, United States, in the North America region.

How does F-Prime make money?

One revenue line is on record: venture Capital Returns.

Who are F-Prime's main competitors?

Direct peers on record are Andreessen Horowitz, General Catalyst, ARCH Venture Partners, Bessemer Venture Partners, Lightspeed Venture Partners, New Enterprise Associates (NEA), Khosla Ventures and OrbiMed. Sequoia Capital is listed as a broad incumbent. GV (Google Ventures) is listed as an emerging player.

Does F-Prime have an API?

No public API is recorded for F-Prime.

What industry is F-Prime in?

F-Prime's product category is Venture Capital Investment. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageVitriVax Announces $87 Million Series C Financing to Advance Lyme Disease Vaccine Candidate into the Clinic and Expand PipelineVitriVax closed an oversubscribed $87 million Series C financing co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures. The funds will advance its Lyme disease vaccine candidate into a first-in-human trial and expand its ALTA platform pipeline. The company also cites no approved Lyme vaccine and up to 50% of patients failing multi-dose regimens.Tech Funding NewsEka Robotics raises $150M at $1.45B valuation led by a16z and F-Prime for dexterous robots — TFNEka Robotics raised a $150M Series A led by a16z and F-Prime, valuing the Cambridge startup at $1.45B post-money. The company's robot picks up 1,500 unfamiliar objects per hour, about 2.5 times the human baseline of 600. Funds will scale its Vision-Force-Action model and speed up customer deployments.BitlyEka is worth $1.45B thanks to a physical AI model that has experts ravingEka Robotics closed a $150 million Series A at a $1.45 billion valuation, led by a16z and F-Prime. Its force-sensitive gripper robot picks up about 1,500 objects per hour, 95% reliably, surpassing human performance. The company is in secretive pilots with industrial customers, aiming to deploy on assembly lines.TechCrunchEka is worth $1.45B thanks to a physical AI model that has experts ravingEka Robotics closed a $150 million Series A at a $1.45 billion valuation, led by a16z and F-Prime. Its force-sensitive gripper robot picks up about 1,500 objects weighing up to 1 kg per hour, exceeding human performance. The company is in secretive pilots with industrial customers, aiming to deploy on assembly lines.MedCity NewsStartup Arboretum Sprouts, Bringing a Precision Medicine Approach to Common DiseasesArboretum LifeSciences, co-founded by Anthony Philippakis, raised $30 million in Series A funding led by GV and F-Prime. The Cambridge-based company provides whole-genome sequencing and analyzes data to guide drug development for common diseases. It expects to sequence half a million people and pursue partnerships by 2027.Pulse 2.0AblePay Health Raises $20 Million Series A Led By F-PrimeAblePay Health raised $20 million in Series A funding led by F-Prime, with participation from A1 Health Ventures and .406 Ventures. The company will use the capital to expand its healthcare affordability platform, citing $591 billion in out-of-pocket spending in 2025. The funding supports product development and expansion into additional healthcare systems.WsjArboretum, With a Fresh $30 Million, Wants to Use Its Genetic Testing for More DiseasesArboretum LifeSciences raised a $30 million Series A led by GV and F-Prime to expand genetic testing beyond cancer and rare disorders. The startup will apply the testing to cardiovascular and metabolic diseases, collaborating with health systems and drugmakers to identify patients for clinical trials.Clinical Trials ArenaR1 Therapeutics secures $80.5m to fund Phase IIb AP306 studyR1 Therapeutics expanded its Series A financing to $80.5m to advance AP306 in a Phase IIb trial for hyperphosphatemia in dialysis-dependent chronic kidney disease patients. The round includes Samsara BioCapital and expects top-line results in the first half of 2027.Venture Capital Access OnlineR1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemiaR1 Therapeutics expanded its Series A financing to $80.5 million, adding Samsara BioCapital to an existing syndicate. The funds will advance AP306, a pan phosphate transporter inhibitor in a global Phase 2b trial for hyperphosphatemia in dialysis patients, with topline data expected in H1 2027.BioSpaceR1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemiaR1 Therapeutics expanded its Series A financing to $80.5 million, adding Samsara BioCapital to an existing syndicate. The funds will advance AP306, a pan phosphate transporter inhibitor in a global Phase 2b trial for hyperphosphatemia in dialysis patients, with topline data expected in H1 2027.